bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock Read more about bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock Read more about bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference Read more about bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
bluebird bio Sells Second Priority Review Voucher for $95 Million Read more about bluebird bio Sells Second Priority Review Voucher for $95 Million
41st Annual J.P. Morgan Healthcare Conference Read more about 41st Annual J.P. Morgan Healthcare Conference
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference Read more about bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer Read more about bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18 Read more about FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting Read more about New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
bluebird bio Sells Priority Review Voucher for $102 Million Read more about bluebird bio Sells Priority Review Voucher for $102 Million